Trademark: 79377711
Word
BIOLINERX
Status Date
Thursday, May 9, 2024
Filing Date
Tuesday, May 23, 2023
Published for Opposition
Tuesday, June 11, 2024
42 Pharmaceutical product development services, namely, pharmaceutical product development through the discovery of compounds that helps for the treatment of a variety of diseases and symptoms; pharmaceutical product development services for a wide variety of diseases and symptoms, namely, neuropathic pain, acute kidney injury, inflammatory bowel disease, adult diabetes, weight loss among cancer patients, bacterial infections, rheumatoid arthritis, celiac disease, psoriasis, solid cancerous tumors, myocardial infarction, schizophrenia and prostate cancer; pharmaceutical product development services of new compounds for use in medicines for oncology patients; pharmaceutical research services; research and development services in the field of biotechnology
Aug 31, 2023
Sn Assigned For Sect 66a Appl From Ib
Feb 21, 2024
Non-Final Action (Ib Refusal) Prepared For Review
Mar 12, 2024
Refusal Processed By Mpu
May 7, 2024
Correspondence Received In Law Office
May 7, 2024
Teas/Email Correspondence Entered
May 7, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
May 7, 2024
Teas Change Of Correspondence Received
May 7, 2024
Teas Change Of Owner Address Received
May 7, 2024
Teas Change Of Domestic Representatives Address
May 7, 2024
Applicant/Correspondence Changes (Non-Responsive) Entered
May 7, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 7, 2024
Teas Response To Office Action Received
May 8, 2024
Approved For Pub - Principal Register
May 22, 2024
Notification Of Notice Of Publication E-Mailed
Apr 2, 2024
Refusal Processed By Ib
Sep 1, 2023
New Application Office Supplied Data Entered
Sep 5, 2023
Application Filing Receipt Mailed
Feb 15, 2024
Assigned To Examiner
Feb 20, 2024
Non-Final Action Written
Mar 13, 2024
Non-Final Action Mailed - Refusal Sent To Ib
Trademark Alertz updated from USPTO on 2030-01-24
